TIMP1 and prostate cancer: In summary, there appears to be a trend of increased expression of MMP-2, -7, -9 and TIMP-1 in the blood and increased expression of MMP-2, -7, -14, -15 and -26 tissue during malignant progression of prostate cancer, but more carefully designed perspective studies are needed to determine the clinical utility of these MMPs as biomarkers in prostate cancer.